Review Article On Analytical Method Development And Method Validation On UV And HPLC Of Drug Losartan

An essential component in the treatment of hypertension and other cardiovascular diseases is the angiotensin II receptor blocker (ARB) losartan. The pharmacological characteristics, clinical uses, and methodological developments made to better understand and utilize losartan are all covered in detail in this review. The development of analytical methods, pharmacokinetic investigations, and creative research approaches that have advanced our comprehension of losartan are highlighted. According to short-term (up to 12 weeks) clinical trials, losartan is just as effective as approved dosages of captopril, atenolol, enalapril, felodipine, and nifedipine at lowering blood pressure (BP) in older people with hypertension (causes a decrease in BP ≤26/20mm Hg). Losartan's effectiveness in treating patients with isolated systolic hypertension (ISH) was comparable to that of atenolol. The antihypertensive efficacy of captopril + hydrochlorothiazide is comparable to that of hydrochlorothiazide added to losartan treatment. Additionally, preliminary data suggests that losartan medication aids in the reduction of left ventricular hypertrophy linked to chronic. The incidence of treatment-related adverse events linked to once-daily losartan (either alone or in combination with hydrochlorothiazide) in elderly patients with hypertension ranged from 19 to 27%; this was comparable to that of felodipine (23%) and nifedipine (21%); on the other hand, losartan was generally better tolerated than captopril (11 vs 16%). Additionally, among individuals with ISH, losartan was more well tolerated (10.4 vs. 23%) than atenolol. Losartan's renal tolerability in heart failure patients was comparable to that of captopril, but losartan was linked to a decreased rate of withdrawal due to adverse events. Patients with mild to moderate renal failure or the elderly don't need to change their dosage, and there is little chance of first-dose